COVID-19 in the WHO African region: using risk assessment to inform decisions on public health and social measures.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
10 05 2021
Historique:
pubmed: 11 5 2021
medline: 8 1 2022
entrez: 10 5 2021
Statut: epublish

Résumé

Successive waves of COVID-19 transmission have led to exponential increases in new infections globally. In this study, we have applied a decision-making tool to assess the risk of continuing transmission to inform decisions on tailored public health and social measures (PHSM) using data on cases and deaths reported by Member States to the WHO Regional Office for Africa as of 31 December 2020. Transmission classification and health system capacity were used to assess the risk level of each country to guide implementation and adjustments to PHSM. Two countries out of 46 assessed met the criteria for sporadic transmission, one for clusters of cases, and 43 (93.5%) for community transmission (CT) including three with uncontrolled disease incidence (Eswatini, Namibia and South Africa). Health system response's capacities were assessed as adequate in two countries (4.3%), moderate in 13 countries (28.3%) and limited in 31 countries (64.4%). The risk level, calculated as a combination of transmission classification and health system response's capacities, was assessed at level 0 in one country (2.1%), level 1 in two countries (4.3%), level 2 in 11 countries (23.9%) and level 3 in 32 (69.6%) countries. The scale of severity ranged from 0 to 4, with 0 the lowest. CT coupled with limited response capacity resulted in a level 3 risk assessment in most countries. Countries at level 3 should be considered as priority focus for additional assistance, in order to prevent the risk rising to level 4, which may necessitate enforcing hard and costly lockdown measures. The large number of countries at level 3 indicates the need for an effective risk management system to be used as a basis for adjusting PHSM at national and sub-national levels.

Identifiants

pubmed: 33966683
doi: 10.1017/S0950268821001126
pii: S0950268821001126
pmc: PMC8712964
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e259

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Science. 2021 Jan 1;371(6524):27-28
pubmed: 33384364
Am J Trop Med Hyg. 2020 Jun;102(6):1145-1148
pubmed: 32372749
BMJ. 2020 Oct 28;371:m4113
pubmed: 33115704
Emerg Microbes Infect. 2020 Dec;9(1):1300-1308
pubmed: 32458760
Ethn Dis. 2020 Sep 24;30(4):693-694
pubmed: 32989369
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451366
Lancet. 2020 Mar 14;395(10227):841-842
pubmed: 32113508
PLoS One. 2020 Jul 10;15(7):e0235730
pubmed: 32649713
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Science. 2020 Aug 7;369(6504):624-626
pubmed: 32764055
Int J Infect Dis. 2020 Sep;98:191-193
pubmed: 32615323

Auteurs

Benido Impouma (B)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.
Institute of Global Health, University of Geneva, Geneva, Switzerland.

Franck Mboussou (F)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Caitlin M Wolfe (CM)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.
College of Public Health, University of South Florida, Tampa, Florida, USA.

Bridget Farham (B)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

George Sie Williams (GS)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Opeayo Ogundiran (O)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Roland Ngom (R)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Milse Nzingou (M)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Antoine Flahault (A)

Institute of Global Health, University of Geneva, Geneva, Switzerland.

Cláudia Torres Codeço (CT)

Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Ambrose Talisuna (A)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Zabulon Yoti (Z)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Olivia Keiser (O)

Institute of Global Health, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH